… ProQR Announces a Proof-of-Concept Nasal Potential Difference … study of QR-010 is now open and enrolling," said Noreen R. Henig, MD, Chief Development Officer of ProQR. "This study is an important proof-of-concept study …
… ProQR Receives € 4.7 million in Innovation Credit from Dutch … CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … or the clinical development of a medicine or device. ProQR was awarded an Innovation credit for the QR-110 …
… ProQR Announces Presentation on QR-421a Program in … and CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … delivered by Dr. Aniz Girach, MD, chief medical officer of ProQR, on QR-421a for Usher Syndrome during the USH2019 …
… ProQR Receives Rare Pediatric Disease Designation from FDA … & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … children,” said Daniel de Boer, chief executive officer of ProQR. “This designation for sepofarsen underscores the …
… ProQR to Highlight a Growing Pipeline During a Research & … the Netherlands, March 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Miami Beach Hotel in Miami Beach, FL, USA at 2:35pm ET. R&D Day On March 14, 2016 starting at 10am ET the company …
… ProQR Announces Enrollment Has Started in Global Phase 1b … said Daniel A. de Boer, Chief Executive Officer of ProQR. "Since the foundation of the company 3 years ago our … study will also assess sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by …
… ProQR Announces Clearance of IND to Start Clinical Trial of … & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel A. de Boer, Chief Executive Officer of ProQR. “QR-421a has shown promising activity in both the …
… ProQR Receives Fast Track Designation from the FDA for QR-110 … for Leber’s Congenital Amaurosis Type 10 Key Updates ProQR receives Fast Track designation by the U.S. Food and … which there is currently nothing available,” said Noreen R. Henig, Chief Medical Officer of ProQR. “We are also …
… ProQR Announces Positive Top-Line Results from the Phase 1/2 … Retinal Disease community as a whole,” said Stephen R. Russell, MD, Schrage Professor of Ophthalmology and Visual … Executive Vice President of Research & Development of ProQR, said, “We are very pleased with the data reported from …